

**From:** SANTE B2 TOBACCO CONTROL  
**Sent:** vendredi 25 février 2022 09:01  
**To:** SANTE B2 TOBACCO CONTROL  
**Subject:** FW: Nicotine pouches follow up

**From:** SANTE B2 TOBACCO CONTROL <[SANTE-B2-TOBACCO-CONTROL@ec.europa.eu](mailto:SANTE-B2-TOBACCO-CONTROL@ec.europa.eu)>  
**Sent:** Friday, August 6, 2021 1:21 PM  
**To:** [REDACTED] <[\[REDACTED\]@iazmp.si](mailto:[REDACTED]@iazmp.si)>  
**Cc:** [REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>; [REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>; [REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>; [REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>; [REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>; [REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>; ANTE  
CONSULT-B2 <[sante-consult-b2@ec.europa.eu](mailto:sante-consult-b2@ec.europa.eu)>; [REDACTED] <[\[REDACTED\]@iazmp.si](mailto:[REDACTED]@iazmp.si)>; [REDACTED] <[\[REDACTED\]@iazmp.si](mailto:[REDACTED]@iazmp.si)>; [REDACTED] <[\[REDACTED\]@iazmp.si](mailto:[REDACTED]@iazmp.si)>; SANTE B2  
TOBACCO CONTROL <[SANTE-B2-TOBACCO-CONTROL@ec.europa.eu](mailto:SANTE-B2-TOBACCO-CONTROL@ec.europa.eu)>  
**Subject:** RE: Nicotine pouches follow up

Dear

Thank you for your prompt feedback. We would be indeed extremely grateful if you could forward the original e-mail to all the MSs.

Please accept our apologies for the lack of clear instructions in this sense and do not hesitate to contact us should you or any of the EMACOLEX members have any additional questions.

Best wishes,

On behalf of Thea Emmerling, Head of Unit  
B2 - Cross-border healthcare and tobacco control  
Health and Food Safety DG (SANTE) - European Commission  
✉ [SANTE-B2-TOBACCO-CONTROL@ec.europa.eu](mailto:SANTE-B2-TOBACCO-CONTROL@ec.europa.eu)

From: [REDACTED] <[\[REDACTED\]@jazmp.si](mailto:[REDACTED]@jazmp.si)>  
Sent: Friday, August 6, 2021 1:02 PM  
To: SANTE B2 TOBACCO CONTROL <[SANTE-B2-TOBACCO-CONTROL@ec.europa.eu](mailto:SANTE-B2-TOBACCO-CONTROL@ec.europa.eu)>  
Cc: [REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>; [REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>;  
[REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>; [REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>;  
[REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>; [REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>;  
[REDACTED] <[\[REDACTED\]@ec.europa.eu](mailto:[REDACTED]@ec.europa.eu)>; SANTE CONSULT-B2 <[sante-consult-b2@ec.europa.eu](mailto:sante-consult-b2@ec.europa.eu)>;  
[REDACTED] <[\[REDACTED\]@jazmp.si](mailto:[REDACTED]@jazmp.si)>; [REDACTED] <[\[REDACTED\]@jazmp.si](mailto:[REDACTED]@jazmp.si)>  
[REDACTED] <[\[REDACTED\]@jazmp.si](mailto:[REDACTED]@jazmp.si)>

**Subject:** RE: Nicotine pouches follow up

Dear \_\_\_\_\_,

We (JAZMP as current chair of the EMACOLEX group) understand that your email is intended for all member states. If our understanding is correct, we can forward your request to other member states. If you want to contact national representatives of EMACOLEX group directly, you can find the latest mailing list below.

[@aemps.es;](#) [@ages.at](#) [@ages.at](#) [@aemps.es;](#) [@aemps.es](#) [@ages.at;](#) [@aemps.es;](#)  
[@aifa.gov.it>;](#) [@alims.gov.rs](#) [@alims.gov.rs;](#) [@amed.md;](#)  
[@amed.md;](#) [@anm.ro](#) [@base.ev.at](#) [@base.ev.at;](#)  
[@basg.ev.at;](#) [@bda.bg>;](#) [@bda.bg;](#) [@bfarm.de;](#)  
[@bfarm.de](#) [@bmg.bund.de](#) [@bmg.ev.at](#) [@bmfg.ev.at;](#)  
[@bvl.bund.de](#) [@canada.ca;](#) [@canada.ca](#) [@canada](#)  
[@ema.europa.eu;](#) [@ema.europa.eu>;](#)  
[@eof.gr>](#) [@eof.gr;](#) [@fagg-afmps.be;](#) [@fagg-afmps.be;](#)  
[@fimea.fi;](#) [@fimea.fi;](#) [@gif.gov.pl;](#) [@gif.gov.pl](#) [@gov.mt;](#)  
[@governmentlegal.gov.uk](#) [@haimed.hr;](#)  
[@hpra.ie;](#) [@hpra.ie;](#) [@hpra.ie>;](#) [@ima.is;](#) [@infarmed.pt;](#)  
[@infarmed.pt;](#) [@iazmp.si>;](#) [@iazmp.si>;](#) [@iazmp.si>;](#)  
[@legemiddelverket.no;](#) [@legemiddelverket.no;](#) [@llv.li](#) [@lakemedelsverket.se;](#)  
[@ms.etat.lu](#) [@ogyei.gov.hu](#) [@ogyei.gov.hu;](#) [@otenet.gr;](#)  
[@pei.de;](#) [@ravimiamet.ee;](#) [@ravimiamet.ee>;](#)  
[@sozialministerium.at](#) [@sukl.cz](#) [@sukl.cz;](#) [@sukl.cz>;](#)  
[@sukl.cz;](#) [@sukl.cz;](#) [@sukl.sk;](#) [@swissmedic.ch;](#)  
[@swissmedic.ch;](#) [@urpl.gov.pl;](#) [@urpl.gov.pl>;](#)  
[@urpl.gov.pl;](#) [@urpl.gov.pl;](#) [@zdravije.gov.rs;](#)  
[@zva.gov.lv;](#) [@zva.gov.lv;](#) [@gov.mt;](#) [@gov.mt;](#)

Feel free to contact us if you have any further questions or requests!

Best regards!



**D** [REDACTED]  
Sektor za splošne zadeve / *General Affairs Division*

**JAVNA AGENCIJA REPUBLIKE SLOVENIJE ZA ZDRAVILA IN MEDICINSKE PRIPOMOČKE**  
**AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES OF THE REPUBLIC OF SLOVENIA**

[www.jazmp.si](http://www.jazmp.si)

In February 2020, a European market report on tobacco-free nicotine identified 17 brands marketed in the EU with 137 product presentations that varied in flavour, nicotine strength and portion weight. It needs to be noted that nicotine is an active ingredient of many medicinal products authorised for smoking cessation.

The European Commission has received requests from Member States regarding the most appropriate regulation of nicotine pouches since these fall out of the scope of the Tobacco Products Directive (2014/40/EU). The major challenge with these products is the absence of tobacco leaf, which is also the main difference between oral tobacco and nicotine pouches.

While these products remain unregulated in most Member States, they are accessible to anyone anywhere without fulfilling the requirements imposed to related products. More so, these products have nicotine in rather high concentrations and are attractive due to a wide variety of flavours. All of these factors together make these products a serious public health threat. We are aware that these products have been subjected to the medicinal products legislation in some Member States, while others considered their categorization as food or tobacco surrogate (specific national legislation).

In order to fully capture the current situation in Member States, we aim to consult the most relevant Member States' groups dealing with the above mentioned areas. For this reason, we would be grateful for your replies to our short electronic [survey](https://ec.europa.eu/eusurvey/runner/ede49243-22a9-450a-40b7-dfc44019c1a6) (please click on the link to access the survey). Your replies will provide an extremely valuable basis for further follow-up, both in your group as well as in the tobacco and possibly food sector (which you may wish to reach out at national level).

The full link to the survey is: <https://ec.europa.eu/eusurvey/runner/ede49243-22a9-450a-40b7-dfc44019c1a6>

We would be very thankful for your feedback **by 15 September 2021** at the latest.

Kind regards,



**European Commission**

Health and Food Safety Directorate General (SANTE)

SANTE B5 Medicines-policy, authorisation and monitoring



B-1049 Brussels, Belgium



**European Commission**

Health and Food Safety Directorate General

SANTE B2: Cross-border healthcare and tobacco



B-1049 Brussels, Belgium

---

To elektronsko sporočilo in vse morebitne priponke lahko vsebujejo informacije zaupne narave, namenjene izključno naslovniku. Če ste elektronsko sporočilo prejeli pomotoma, prosimo, da obvestite pošiljatelja, sporočilo pa takoj izbrišete ali uničite. V takšnem primeru je prepovedano kakršno koli razkritje, kopiranje ali pošiljanje tega elektronskega sporočila in njegove morebitne priponke tretjim osebam.

This e-mail and its attachments are for the intended recipient only. It may contain confidential or privileged information, some or all of which may be legally privileged. If you received this e-mail by mistake you are kindly asked to notify the sender by replying to this email, and immediately delete or destroy this e-mail. You must not use, copy, print, disclose, distribute the content of this e-mail.